Zobrazeno 1 - 4
of 4
pro vyhledávání: '"J. R. Fortuny Olive"'
Autor:
M. Vallvé Elias, R. Sánchez González, E. Carrió Diez, G. Mateu Codina, J. R. Fortuny Olive, M. Pérez Carre, C. Macias Castellví, J. Marti Bonany, M. I. Martínez Casamitjana
Publikováno v:
European Psychiatry. 64:S658-S658
IntroductionClozapine is the most effective antipsychotic for treatment resistant schizophrenia but adverse reactions to clozapine include neutropenia. Patients with COVID-19 infection frequently experience lymphopenia, but not neutropenia.The impact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::260a57330832dd7bbb3152ea7440445d
https://doi.org/10.1192/j.eurpsy.2021.1748
https://doi.org/10.1192/j.eurpsy.2021.1748
Autor:
R. Sánchez González, F. Lana Moliner, E.J. Pérez Sánchez, C. Macias Castellví, E. Carrió Diez, M. Pérez Carre, J. R. Fortuny Olive, J. Marti Bonany, M. I. Martínez Casamitjana
Publikováno v:
European Psychiatry. 64:S299-S299
IntroductionClozapine is the most effective antipsychotic for treatment resistant schizophrenia. In patients treated with clozapine, COVID-19 infection may result in complications including an increased risk of pneumonia, clozapine toxicity, and disr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::922f989bd7e92a07af1b41577fcadcc7
https://doi.org/10.1192/j.eurpsy.2021.803
https://doi.org/10.1192/j.eurpsy.2021.803
Autor:
S. Ramos Perdigues, X. Valiente Torrelles, L. Ortiz Sanz, P. Salgado Serrano, F. Dinamarca, E. Jove Badia, V. Pérez Solá, J. R. Fortuny Olive, A. Mane Santacana
Publikováno v:
European Psychiatry. 33:S584-S584
IntroductionSchizophrenia is a developmental disorder that includes non-psychiatric abnormalities [2]. Metabolic abnormalities prior to antipsychotic treatment exist. The clozapine metabolic profile causes clozapine underuse in resistant schizophreni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f5d147363a4dbd3d421b2e4fce18a65e
https://doi.org/10.1016/j.eurpsy.2016.01.2169
https://doi.org/10.1016/j.eurpsy.2016.01.2169
Autor:
F. Dinamarca, J. R. Fortuny Olive, L. Ortiz Sanz, P. Salgado Serrano, E. Jove Badia, A. Mane Santacana, S. Ramos Perdigues, X. Valiente Torrelles, V. Pérez Solá
Publikováno v:
European Psychiatry. 33:s261-s261
IntroductionFor resistant schizophrenia, the only approved treatment is clozapine. However, clozapine is underused, mainly due to its wide range of side-effects. Secondary effects differ amongst antipsychotics (Leucht et al., 2009). Despite that ther
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::06516da1ab7bb64b4ae88334cab85f2d
https://doi.org/10.1016/j.eurpsy.2016.01.667
https://doi.org/10.1016/j.eurpsy.2016.01.667